{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T18:19:13Z","timestamp":1763144353201,"version":"3.45.0"},"reference-count":13,"publisher":"Microbiology Society","issue":"11","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018289","name":"Shinnihon Foundation of Advanced Medical Treatment Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018289","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,14]]},"abstract":"<jats:p>\n                    <jats:bold>Introduction.<\/jats:bold>\n                    In antibiotic chemotherapy, an antimicrobial agent is selected based on MIC, which is determined by a test method using the principle of the broth microdilution. However, it does not provide a viable count in the mutant selection window. In this study, we used turbidimetry and visual judgement to examine the validity of the selection of various antibiotics to treat\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    based on MIC determination after 24\u2009h of incubation.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods.<\/jats:bold>\n                    The antibiotics used in this study were piperacillin (PIPC), imipenem (IPM), meropenem, ciprofloxacin and amikacin (AMK). The strains used were 30\n                    <jats:italic>P<\/jats:italic>\n                    .\n                    <jats:italic>aeruginosa<\/jats:italic>\n                    strains clinically isolated that were susceptible to all the antibiotics used, and the standard PAO1 strain. The viable count was measured after exposure for 3 and 24\u2009h to therapeutic concentrations of various antibiotics, at which time turbidity was examined visually or by transmittance. In addition, the MPCs of IPM and PIPC were measured.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results.<\/jats:bold>\n                    In this study, 10\u00b2\u201310\u2078 c.f.u. ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    of\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    survived exposure to PIPC, IPM and AMK at concentrations 2.5\u201380 times the MIC despite high drug concentrations. No turbidity was observed in the culture medium. Furthermore, both IPM and PIPC showed high mutant prevention concentration (MPC), with 64.5% of strains in IPM and 10% of strains in PIPC showing intermediate or resistance after 24\u2009h.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions.<\/jats:bold>\n                    Choosing an appropriate antibiotic based on exceeding the MIC may be insufficient. While the PK\/PD theory focuses on MIC, measuring MPC alongside MIC is urgent in clinical practice for optimal antibiotic selection.\n                  <\/jats:p>","DOI":"10.1099\/jmm.0.002093","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T18:16:17Z","timestamp":1763144177000},"source":"Crossref","is-referenced-by-count":0,"title":["Limitations of antimicrobial agent choice based on MIC value against Pseudomonas aeruginosa"],"prefix":"10.1099","volume":"74","author":[{"given":"Yurina","family":"Tamura","sequence":"first","affiliation":[{"name":"Division of Clinical Infectious Disease and Chemotherapy, Tohoku Medical and Pharmaceutical University, Graduate School of Pharmacy, 4-4-1, Komatsushima, Aoba-ku, Sendai, 981-8558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Division of Clinical Infectious Disease and Chemotherapy, Tohoku Medical and Pharmaceutical University, Graduate School of Pharmacy, 4-4-1, Komatsushima, Aoba-ku, Sendai, 981-8558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tohoku Rosai Hospital, 4-3-21, Dainohara, Aoba-ku, Sendai, 981-8563, Japan"},{"name":"Division of Clinical Infectious Disease and Chemotherapy, Tohoku Medical and Pharmaceutical University, Graduate School of Pharmacy, 4-4-1, Komatsushima, Aoba-ku, Sendai, 981-8558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Clinical Infectious Disease and Chemotherapy, Tohoku Medical and Pharmaceutical University, Graduate School of Pharmacy, 4-4-1, Komatsushima, Aoba-ku, Sendai, 981-8558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7419-3293","authenticated-orcid":false,"given":"Shigeru","family":"Fujimura","sequence":"additional","affiliation":[{"name":"Division of Clinical Infectious Disease and Chemotherapy, Tohoku Medical and Pharmaceutical University, Graduate School of Pharmacy, 4-4-1, Komatsushima, Aoba-ku, Sendai, 981-8558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"345","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70036-2"},{"key":"R2","article-title":"EUCAST reading guide for broth microdilution, version 5.0. 2024","year":"2024"},{"key":"R3","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. CLSI standard M07","year":"2024"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-021-06609-6"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.04.005"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-020-00685-5"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2023.123592"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.01186-21"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1780-1787.2001"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139836"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10070851"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519864181"},{"key":"R13","series-title":"Section 25 Antimicrobial Therapy: General Considerations","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/med\/9780190888367.003.0206","volume-title":"Schlossberg\u2019s Clinical Infectious Disease","author":"Cunha","year":"2021"}],"container-title":["Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.002093?crawler=true&mimetype=application\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T18:16:18Z","timestamp":1763144178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.002093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,14]]}},"URL":"https:\/\/doi.org\/10.1099\/jmm.0.002093","relation":{},"ISSN":["0022-2615","1473-5644"],"issn-type":[{"value":"0022-2615","type":"print"},{"value":"1473-5644","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]}}}